Cytoxan
Cytoxan is a pharmaceutical drug with 33 clinical trials. Currently 8 active trials ongoing. Historical success rate of 82.4%.
Success Metrics
Based on 14 completed trials
Phase Distribution
Phase Distribution
15
Early Stage
13
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
70.0%
14 of 20 finished
30.0%
6 ended early
8
trials recruiting
33
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Stem Cell Transplantation in Crohn's Disease
Clinical Trials (33)
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Stem Cell Transplantation in Crohn's Disease
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase Suicide Safety Switch, Neuroblastoma, GRAIN
Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
A Phase 2 Trial for Patients With Metastatic Solid Cancer
Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
Umbilical Cord Blood Transplant for Congenital Pediatric Disorders
A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH
Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan
A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma
Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma
Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 33